Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Stockwatch: Fireworks Or Ballistic Missiles In Biotechnology?

Executive Summary

Last week saw the NASDAQ Biotechnology Index (NBI) finish up 2.9%, outperforming a flat week for the broad market S&P 500 index. In the past six months this has been a reasonably rare event although it was often the case in the last biotech bull market that ended last summer. While much of the NBI's performance came from the relief rally on Friday, May 20, some commentators on social media were hailing it as the start of a recovery in biotechnology.

Advertisement

Related Content

Ports, Prosthetics Take Blame In Partial Hold For Aduro’s Immunotherapy Trials
Immuno-Oncology Data Drive Deal Dollars Higher
Immuno-Oncology's Next Wave: Key Targets And Emerging Players
Acorda Drops Epilepsy Candidate Once Central To Its Revenue Forecasts
Trevena's Play Out Of Pain Space Fails In Phase IIb
Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel